$INCY News

Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years

Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target

Incyte Stock: Is Wall Street Bullish or Bearish?

Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130

Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup

Incyte Sales Growth Drives Share Price Gains

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mizuho Maintains Outperform on Incyte, Raises Price Target to $137

Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target

Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years

Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?

Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong

European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)

Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis

Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109

Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Guggenheim Maintains Buy on Incyte, Raises Price Target to $150